Clinical Trials Search
Clinical Trial 19406
Cancer Type: Thoracic
Study Type: Treatment
NCT#: NCT03377023
Phase: Phase I/II
Prinicipal Investigator: Jhanelle Gray
Study Title
Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Summary
The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer. Researchers also want to find out if the combination of nivolumab, ipilimumab and nintedanib is safe and tolerable.
Objective
Phase I (Dose Escalation): Determine the MTD and RP2D of concurrent administration of nivolumab, ipilimumab, and nintedanib. Phase II (Single Arm Cohorts): To determine the efficacy of concurrent administration of nivolumab, ipilimumab, and nintedanib in NSCLC patients. (1) Arm A: Newly diagnosed or treatment-naïve patients, with a target ORR of 50%, or (2) Arm B: Patients who have been previously exposed to immunotherapy, such as anti-PD-1, anti-PD-L1 or anti-CTLA-4, with a target ORR of 20%.
Therapies
Medications
BMS-936558 (Nivolumab); Ipilimumab (); Nintedanib (); Nivolumab (Opdivo); Yervoy (Ipilimumab)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.